Similar articles

• Managing conflicts of interest in clinical practice guidelines.

  Wani S, Vargo J, Wallace M. Wani S, et al. Gastrointest Endosc. 2020 Feb;91(2):274-275. doi: 10.1016/j.gie.2019.11.019. Epub 2020 Jan 22. Gastrointest Endosc. 2020. PMID: 32036937 No abstract available.
• Response.

  Bansal R, Khan R, Scaffidi MA, Grover SC. Bansal R, et al. Gastrointest Endosc. 2020 Oct;92(4):979-980. doi: 10.1016/j.gie.2020.06.026. Gastrointest Endosc. 2020. PMID: 32964842 No abstract available.
• Enforcement policy: recalls (including product corrections)--guidelines on policy, procedures, and industry responsibilities.

  [No authors listed] [No authors listed] Fed Regist. 1978 Jun 16;43(117):26201-21. Fed Regist. 1978. PMID: 10316619 No abstract available.
• Macro trends in pharmaceutical innovation.

  Cohen FJ. Cohen FJ. Nat Rev Drug Discov. 2005 Jan;4(1):78-84. doi: 10.1038/nrd1610. Nat Rev Drug Discov. 2005. PMID: 15688075 Review.
• Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?

  Hewitt NJ, de Kanter R, LeCluyse E. Hewitt NJ, et al. Chem Biol Interact. 2007 May 20;168(1):51-65. doi: 10.1016/j.cbi.2006.12.009. Epub 2006 Dec 28. Chem Biol Interact. 2007. PMID: 17239835 Review.